



BREAKTHROUGH PEPTIDE THERAPEUTICS

Chair Appointment & Director Resignation

Perth, Australia, 11 April 2016: Phylogica Limited (ASX: PYC) has appointed Ms Stephanie Unwin as non-executive Chair of the board of directors, with immediate effect.

Ms Unwin succeeds Mr Bruce McHarrie as Chair, who is today resigning his position with the Board to focus on a recent full time executive appointment with another organisation. Mr McHarrie was a co-founder of Phylogica whilst at the Telethon Kids Institute and has been a director since its inception. The board takes the opportunity on behalf of shareholders to thank him for his dedicated and meritorious contribution to Phylogica.

Ms Unwin's expertise in commercialisation, organisational transformation and strategic planning makes her particularly well suited to the role as Chair where she will oversee all of these key activities during the next pivotal phase of the company's development.

For further information, please contact:

Dr Richard Hopkins

Tel: +61 8 9489 7855

Email: richardh@phylogica.com

About Phylogica

Phylogica Limited (ASX: PYC) is an oncology-focussed drug discovery company developing a new generation of biologics-based therapies against intracellular cancer targets. Phylogica controls access to the world's most structurally diverse source of peptides - called Phylomers. The company specialises in peptide-based drug delivery and discovery solutions to access intractable intracellular cancer targets with unprecedented efficiencies. Phylogica is advancing its proprietary oncology programmes which are focussed on developing first in class therapies against targets including MYC and STAT5 that play a critical role in many common cancers but have proven undruggable with conventional small molecule therapies. Within the last six years the company has entered into discovery collaborations with Roche, Genentech, MedImmune, Pfizer, Janssen and Cubist Pharmaceuticals.